Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 33
Semaglutide and depression: 2026 review
A 2026 meta-analysis found no significant depression risk from semaglutide, but high heterogeneity and real-world signals leave the picture unsettled.
BPC-157 and TB-500 after shoulder surgery
Animal studies link BPC-157 and TB-500 to tendon healing, but controlled human evidence for orthopaedic surgery is essentially absent.
Semaglutide and body anxiety explained
Semaglutide users often report new health anxieties about muscle loss and nutrition. Here is what the research actually shows and what remains unknown.
Semaglutide bloating and nausea: trial data
Nausea, bloating and diarrhoea top the side-effect list for semaglutide. Here is what the STEP trial data says about how common they are and why.
What semaglutide does to daily life in MASH
A new ESSENCE analysis puts a number on how people with MASH feel on semaglutide: a small EQ-5D utility gain, and why payers will care about it.
Semaglutide and reward: what research shows
GLP-1 receptors sit inside the brain's dopamine reward circuit. Early trials suggest semaglutide may reduce craving well beyond food.
Stapled semaglutide variants, explained
A new chemistry paper built stapled variants of a semaglutide fragment that last longer in serum; here is what that does and does not show.
Surgery vs semaglutide for heart outcomes
A large real-world study compared semaglutide with bariatric surgery on heart outcomes in obesity. Here is what it found and what it cannot prove.
How semaglutide produces weight loss
Semaglutide works mainly in the brain, suppressing appetite via GLP-1 signalling. Here is what the STEP trials found and what stops when the drug stops.
Tirzepatide in youth: first real-world data
A study of 74 youth prescribed tirzepatide at three clinics found lower blood sugar and BMI. What can the first real-world numbers actually show?
Do other diabetes drugs stop on a GLP-1?
In 3,660 adults starting a GLP-1 or tirzepatide, the count of other glucose-lowering drugs fell for 17.2% of patients and rose for 44.0%.
GLP-1 drugs: how background therapy shifts
A 3,660-patient Polish study found 44% of patients on new incretin-class drugs had more background agents added, 39% saw no change, and 17% had agents removed.